It was a tough month for these popular shares. The post Why these top ASX shares sank 10%+ in April appeared first on The ...

First-year biomedical engineering student Kaitlin Bertrand, who was born with Fraser Syndrome, has been awarded the 2026 ...

MPR spoke with Dr Daniela Carvalho, an investigator in the CHORD trial, the results form which formed the basis for the approval of Otarmeni.

When hearing aids are no longer effective, Ryder Boen tries a cochlear implant. As it’s turned on, he’s overwhelmed by what ...

The decision to place cochlear implants in both ears at the same time in young children may better shape brain development ...

The US Food and Drug Administration (FDA) has approved lunsotogene parvec-cwha (Otarmeni), the first gene therapy for genetic ...

The treatment, the first of its kind, was approved by the Food and Drug Administration on Thursday. “Our baby was born deaf, ...

Cochlear shares crashed nearly 41% on Wednesday in a record daily fall, ‌after the Australian hearing implants maker slashed its forecast for annual earnings, citing weak trading conditions and ...

Cochlear now expects annual underlying net profit of between A$290 million and A$330 million. It had previously guided underlying net profit to be at the lower end of a A$435 million-A$460 million ...

A woman with a rare condition that causes hearing- and vision-loss lit up when a cochlear implant was activated in one of her ...

Abstract: Cochlear implants (CIs) have proven to be successful at restoring the sensation of hearing in people who suffer from profound sensorineural hearing loss. CI users generally achieve good ...

Abstract: Cochlear implants stimulate the auditory nerve with the outputs of a bank of narrow-band filters. We propose that cochlear implant users are better able to perceive speech when these ...